Blair William & Co. IL Has $342,000 Stock Position in Repligen Corporation $RGEN

Blair William & Co. IL boosted its position in shares of Repligen Corporation (NASDAQ:RGEN) by 32.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,746 shares of the biotechnology company’s stock after purchasing an additional 676 shares during the period. Blair William & Co. IL’s holdings in Repligen were worth $342,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Twin Tree Management LP acquired a new stake in Repligen during the first quarter valued at $29,000. Signaturefd LLC boosted its position in Repligen by 65.3% during the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 128 shares during the last quarter. Center for Financial Planning Inc. boosted its position in Repligen by 110.3% during the first quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 193 shares during the last quarter. GAMMA Investing LLC boosted its position in Repligen by 40.1% during the first quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 274 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd acquired a new stake in Repligen during the first quarter valued at $132,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Trading Down 1.3%

Shares of RGEN opened at $152.60 on Friday. Repligen Corporation has a 12-month low of $102.96 and a 12-month high of $182.52. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $8.59 billion, a price-to-earnings ratio of -610.38, a P/E/G ratio of 2.86 and a beta of 1.08. The stock’s 50-day moving average price is $128.81 and its 200 day moving average price is $126.33.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The firm had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. During the same quarter in the prior year, the firm earned $0.40 earnings per share. The company’s revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, research analysts predict that Repligen Corporation will post 1.72 earnings per share for the current year.

Wall Street Analyst Weigh In

RGEN has been the topic of several recent research reports. Weiss Ratings restated a “sell (d)” rating on shares of Repligen in a report on Wednesday, October 8th. Stephens upgraded Repligen to an “overweight” rating and set a $160.00 target price on the stock in a report on Tuesday, July 22nd. Hsbc Global Res upgraded Repligen to a “strong-buy” rating in a report on Wednesday, October 1st. Royal Bank Of Canada restated an “outperform” rating and set a $205.00 target price on shares of Repligen in a report on Tuesday, September 2nd. Finally, Barclays raised their target price on Repligen from $150.00 to $160.00 and gave the company an “overweight” rating in a report on Thursday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $169.62.

Insider Transactions at Repligen

In other news, Director Martin D. Madaus purchased 1,800 shares of the stock in a transaction that occurred on Friday, August 8th. The shares were purchased at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the purchase, the director directly owned 1,800 shares of the company’s stock, valued at approximately $201,834. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.20% of the stock is owned by corporate insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.